乳腺癌是中国女性人群中最常见的恶性肿瘤之一。然而，详细介绍最新流行病学数据和可归因疾病负担的综合报告尚未得到广泛记录。 2018年，中国700个基于人群的癌症登记处记录了高质量的癌症监测数据。我们提取了女性乳腺癌的数据（国际疾病分类，第十次修订版[ICD-10]：C50），并根据2010年至2018年的基线数据和相应趋势估计了2022年的发病率和死亡率。病理类型根据肿瘤学 ICD，第三版代码。伤残调整生命年 (DALY) 计算为损失生命年 (YLL) 与伤残生存年 (YLD) 之和。 2022 年，中国新增女性乳腺癌病例约 357,200 例，死亡人数 75,000 人，占分别占新发癌症病例和死亡总数的 15.59% 和 7.94%。年龄标准化发病率 (ASIR) 为每 10 万人 33.04 例。按病理类型分析，乳头状肿瘤、浸润性乳腺癌、罕见肿瘤和唾液腺型肿瘤、其他类型的ASIR分别为1.13/10万、29.79、0.24、1.88/10万。年龄标准化死亡率（ASMR）为每10万人中有6.10人。中国共发现女性乳腺癌 DALY 2,628,000 例，其中 YLL 2,278,300 例，YLD 349,700 例。城市地区的 ASIR、ASMR 和 DALY 年龄标准化率 (ASR) 始终高于农村地区。我们观察到，与 55 岁以下女性相比，55 岁以上女性的 DALY 的 ASIR 和 ASR 增加了四倍，ASMR 增加了八倍。这些数据为了解女性乳腺癌的最新流行病学提供了宝贵的见解。中国并强调制定疾病预防和控制策略的紧迫性。版权所有 © 2024 中华医学会，由 Wolters Kluwer, Inc. 根据 CC-BY-NC-ND 许可制作。

Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.